Multispecific Molecules Using TCR Heterodimerization Domains
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies face challenges in producing correctly assembled multispecific molecules with a natural immunoglobulin-like structure, particularly in incorporating non-immunoglobulin heterodimerization domains like T cell receptor (TCR) constant domains, which are essential for effective cancer treatment.
Innovation Solution
The development of multispecific molecules comprising non-immunoglobulin heterodimerization domains, specifically TCR constant domains, connected via linkers to immunoglobulin CH2 domains, allowing for correct pairing and assembly, enabling the production of bispecific antibodies that can target cancer antigens effectively.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-immunoglobulin heterodimerization domains (e.g., TCR constant domains) are incorporated into multispecific molecules, then the ability to target cancer antigens effectively is improved, but the complexity of correct assembly and pairing increases
Solution Approach 1:
The patent introduces asymmetric heterodimerization domains (TCRα constant domain and TCRβ constant domain) with distinct amino acid sequences that enable directional and specific pairing. This asymmetric design ensures that only the correct heavy chain pairs with the correct light chain, reducing mispairing complexity while maintaining effective cancer targeting
Solution Approach 2:
The multispecific molecule is divided into distinct functional segments: antigen-binding moieties (ABMs), immunoglobulin CH2 domains, and non-immunoglobulin heterodimerization domains. This segmentation allows each component to be optimized independently for its specific function while simplifying the overall assembly process through modular construction
2Stability of the object's composition
If non-immunoglobulin heterodimerization domains are used to promote stable association, then the stability of heavy chain pairing is improved, but the manufacturing process complexity increases
Solution Approach 1:
The heterodimerization domains are designed to automatically self-assemble into stable heterodimers through intrinsic structural properties and specific interaction interfaces. The TCRα and TCRβ constant domains spontaneously pair in the correct configuration without requiring external assembly assistance, thereby stabilizing heavy chain pairing while simplifying manufacturing by eliminating complex assembly steps
3Reliability
If multisspecific molecules with natural immunoglobulin-like structure are produced, then the binding ability to cancer antigens is improved, but the difficulty of detecting and measuring correct assembly increases
Solution Approach 1:
The patent employs differential labeling strategies where specific domains or chains are tagged with detectable markers (analogous to color changes). This allows researchers to easily distinguish correctly assembled multisspecific molecules from misassembled products, thereby maintaining high antigen binding ability while significantly reducing the difficulty of detecting and measuring correct assembly
Data Source
Figure 1A
Figure 1B
Figure 2A~2B
AI summary
Multispecific molecules comprising a non-immunoglobulin heterodimerization domain (e.g., TCRα/β constant domains), methods of making, and methods of using the same, are disclosed herein.